

## **Primary Care Diabetes & Obesity Society – Endorsement guide**

Endorsement enables the society to provide support and recognition for important pieces of work from other organisations. PCDO Society endorsement grants permission to organisations to use our endorsement on specific resources, events or conferences that are considered to make a valued contribution to patient care.

* We **endorse** selected materials and events from organisations such as Royal Colleges, clinical specialist interest groups and associated charities and patient organisations.
* We **do not endorse** materials or events from commercial organisations, including training companies and other profit-making organisations outside of the NHS.
* We endeavour to complete the endorsement process within 6–8 weeks upon receipt of an Endorsement Application Form. PCDO reserves the right to decline to review and/or endorse resources.

## Endorsement eligibility

|  |  |
| --- | --- |
| **Materials that may be eligible for endorsement:**  | **Organisations that may apply for endorsement:**  |
| • Professional guidance, standards, principles • Tools to support primary care• Patient-facing resources • Multidisciplinary initiatives  | • Clinical specialist interest groups • Royal Colleges • NHS/HSE/equivalent organisations • Charities and patient groups  |

## PCDO Society criteria for endorsement

**PCDO will not endorse:**

* Specific compound-related content or activities (i.e. compounds at level 5 of the ATC classification system; see Appendix for more information).
* Branded activities (commercial, product-marketing activities or content).

**PCDO, after reviewing content for scientific validity and academic value and relevance for good clinical practice in primary care, can choose to endorse:**

* Educational and clinical resources that enhance knowledge, skill or professionalism aimed at improving quality of care and quality of life of people living with diabetes, multiple long-term conditions and/or obesity.

## Conflict of interest disclosure

In selecting reviewers, PCDO endeavours to take account of conflicts of interest. No individual with a connection to the development of the resource in question should be part of the reviewing panel.

## How to apply for an endorsement

In order to apply for an endorsement, please complete the following form. Please note, the application process will be quicker if you fill out the application form with as much detail as possible, to enable the team to process the endorsement more quickly.

The information you provide on this form will only be used for the purpose of this work and will not be passed on to third parties.

The statement of endorsement allows the recipient to add the PCDO logo with the text “Endorsed by Primary Care Diabetes & Obesity Society as being in the scientific or social interest of primary care practitioners”.



## **Application for endorsement**

**Date:** dd/mm/yyyy

## About the applicant

|  |  |
| --- | --- |
| **Name** |  |
| **Job title** |  |
| **Affiliation** |  |
| **Phone number** |  |
| **Email** |  |
| **Organisation** (e.g. Royal College, clinical specialist interest group, charity, patient association) |  |

## About the activity

|  |  |
| --- | --- |
| **Type of activity** (e.g. publication, tool, CPD module, meeting) |  |
| **Owner (organiser) of the activity** |  |
| **Intended audience** |  |
| **Aims/objectives** |  |
| **Brief description of activity** |  |
| **Funding source** (if applicable) Any industry funding is required to be arms-length for PCDO to endorse |  |
| **URL** (if online) |  |
| **Role of PCDO** (please state whether to endorse, review, advise or contribute) |  |

## **Endorsement process**

PCDO will review content for scientific validity, academic value and relevance for good clinical practice in primary care.

PCDO will endeavour to review as quickly as practically possible; however, given that all our reviewers are practising clinicians, it is not possible to specify a time frame.

## **Quality checklist**

As a minimum, the content should meet the following criteria. **Please confirm that these have been met by checking the boxes below**.

## Authorship

[ ]  All authors listed

[ ]  All conflicts of interest disclosed

## Academic rigour

[ ]  Original work with sources appropriately cited or acknowledged

[ ]  Evidence-based

[ ]  Peer reviewed

[ ]  Date of next review (to ensure PCDO can review again and avoid endorsing out-of-date information)

## Aligns with PCDO Society policy and national agenda

[ ]  Supports the delivery of high-quality care of people with diabetes, obesity and long-term conditions

[ ]  Includes primary care professionals as target audience

[ ]  Involvement and input of primary care specialists in diabetes, obesity and/or long-term conditions

## **Submitting this application**

Please submit this form, together with accompanying documents, to the PCDO Society secretariat: pcdos@omniamed.com

## **Appendix. Compound-related content activities.**

In the anatomical therapeutic chemical (ATC) classification system, active substances are classified in a hierarchy with five different levels:

1. Anatomical
2. Therapeutic (drug class)
3. Pharmacological (drug group)
4. Chemical subgroup (drug family)
5. Chemical substance (drug compound)

For example, metformin is classified as:

A – Alimentary tract and metabolism
A10 – Drugs used in diabetes
A10B – Blood glucose lowering drugs, excl. insulins
A10BA – Biguanides
A10BA02 – Metformin

PCDO Society does not endorse individual drugs which would sit at ATC level 5 (e.g. canagliflozin, dapagliflozin and empagliflozin); however, it will endorse compounds at ATC level 4 (e.g. SGLT2 inhibitors as a class).